In this current study, we investigated whether the inclusion of alternative treatments (for instance, cytokine-induced killer cells) and variable genetic backgrounds (NCI-H2228: EML4-ALK, A549: KRAS mutation, HCC-78: ROS1 rearrangement) within the same cancer type can help to provide an advantageous therapeutic paradigm in NSCLC. This evidence concerns the gene EML4 and hepatocellular carcinoma.